Heart and lung involvement in systemic sclerosis;Atteintes cardiaques et pulmonaires sclérodermiques

Revue du Praticien

Volumn 52, Issue 17, 2002, Pages 1901-1907

  Launay, David ^a   Hachulla, Éric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PENICILLAMINE;

CARDIOMYOPATHY; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DOPPLER ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; FOLLOW UP; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINAL FIBROSIS; LUNG COMPLICATION; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MICROANGIOPATHY; PERICARDITIS; PULMONARY HYPERTENSION; REVIEW; SKIN FIBROSIS; SUDDEN DEATH; SYSTEMIC SCLEROSIS;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; PROGNOSIS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 0036846519     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis. Demographic, clinical and serologic features and survival in 1012 Italian patients. Medicine 2002; 81: 139-53.
2. D'Angelo WA, Fries JF, Masi AT et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
3. Clements PJ. Systemic sclerosis (scleroderma) and related disorders: Clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 1-16.
4. Follansbee WP, Curtiss El, Rahko PS et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 1985; 79: 183-92.
5. Milesi-Lecat AM, Aumaitre O, Schmidt J et al. Mécanismes de l'atteinte cardiaque dans la sclérodermie systémique. (À propos de trois observations). Rev Med Interne 1995; 16: 319-24.
6. Murata I, Takenaka K, Shinohara S et al. Diversity of myocardial involvement in systemic sclerosis: An 8-year study of 95 Japanese patients. Am Heart J 1998; 135: 960-9.
7. Nakajima K, Taki J, Kawano M et al. Diastolic dysfunction in patients with systemic sclerosis detected by gated myocardial perfusion SPECT: An early sign of cardiac involvement. J Nucl Med 2001; 42: 183-8.
8. Follansbee WP, Curtiss El, Medsger TA Jr et al. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984; 310: 142-8.
9. Mouthon L, Agard C.Treating systemic sclerosis in 2001. Joint Bone Spine 2001; 68: 393-402.
10. Antoniades L, Sfikakis PP, Mavrikakis M.Glucocorticoid effects on myocardial performance in patients with systemic sclerosis. Clin Exp Rheumatol 2001; 19: 431-7.
11. Follansbee WP. Organ involvement: Cardiac. In: Clements PJ, Furst DE (ed.). Systemic Sclerosis. Baltimore: Williams & Waverly, 1995: 333-64.
12. Paradiso M, Gabrielli F, Coppotelli L et al. Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. Int J Cardiol 1996; 53: 171-7.
13. Kostis JB, Seibold JR, Turkevich D et al. Prognostic importance of cardiac arrhytmias in systemic sclerosis. Am J Med 1988; 84: 1007-15.
14. Sanchez O, Humbert M, Sitbon O et al. Hypertension artérielle pulmonaire associée aux connectivites. Rev Med Interne 2002; 23: 41-54.
15. Koh ET, Lee P, Gladman DD et al. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996; 35: 989-93.
16. Marie I, Levesque H, Hatron PY et al. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie II. Hypertension artérielle pulmonaire isolée, cancer bronchopulmonaire, hémorragie alvéolaire. Rev Med Interne 1999; 20: 1017-27.
17. Salerni R, Rodnan GP, Leon DF et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).Ann Intern Med 1977; 86: 394-9.
18. Launay D, Hachulla E, Hatron PY et al. Dépistage de l'hypertension artérielle pulmonaire au cours de la sclérodermie systémique: Étude d'une cohorte de 67 patients. Rev Med Interne 2001; 22: 819-29.
19. LeRoy EC. Pulmonary hypertension: The bête noire of the diffuse connective tissue diseases. Am J Med 1991; 90: 539-40.
20. Altman RD, Medsger TA Jr, Block DA et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
21. Stupi AM, SteenVD, Owens GR et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
22. Sitbon O, Brenot F, Denjean A et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 384-9.
23. Rich S, Kaufmann S, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
24. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-34.
25. Humbert M, Sanchez O, Fartoukh M et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue disease: Results of a pilot study. Eur Respir J 1999; 13: 1351-6.
26. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-4.
27. Launay D, Hachulla E, Hatron PY et al. Aerosolized iloprost in CREST syndrome related pulmonary hypertension. J Rheumatol 2001; 28: 2252-6.
28. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
29. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
30. Pigula FA, Griffith BP, Zenati MA et al. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997; 64: 1630-4.
31. Sanchez O, Humbert M, Sitbon O et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-7.
32. Black CM, du Bois RM. Organ involvement: pulmonary. In: Clements PJ, Furst DE (ed.). Systemic Sclerosis. Baltimore: Williams & Wilkins, 1996: 299-331.
33. Marie I, Levesque H, Dominique S et al. Atteinte pulmonaire au cours de la sclérodermie systémique. Partie I. Pneumopathie interstitielle chronique fibrosante. Rev Med Interne 1999; 20: 1004-16.
34. Remy-Jardin M, Remy J, Wallaert B et al. Pulmonary involvement in progressive systemic sclerosis: Sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993; 188: 499-506.
35. Remy-Jardin M, Beuscart R, Sault MC et al. Subpleural micronodules in diffuse infiltrative lung diseases: Evaluation with thin section CT scans. Radiology 1990; 177: 133-9.
36. Witt C, Borges AC, John M et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: Broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 635-40.
37. de Clerck LS, Dequeker J, Francx L et al. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term follow up study. Arthritis Rheum 1987; 30: 643-50.
38. Broll H, Tausch G, Eberl R. [Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl).]Wien Klin Wochenschr 1976; 88: 292-5.
39. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
40. Kyndt X, Hebbar M, Queyrel V et al. Sclérodermie systémique et cancer. Recherche de facteurs prédictifs de cancer chez 123 patients sclérodermiques. Rev Med Interne 1997; 18: 528-32.